| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Nicoletta Biglia | Q51829498 |
| P2093 | author name string | Stefano Lello | |
| Rossella E Nappi | |||
| Silvia Maffei | |||
| P2860 | cites work | Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 |
| Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial | Q29615226 | ||
| Clinical proteomics--insights into pathologies and benefits for patients. | Q30977441 | ||
| Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial. | Q31135405 | ||
| Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy | Q32140442 | ||
| Receptor profiling and endocrine interactions of tibolone | Q34163773 | ||
| National use of postmenopausal hormone therapy: annual trends and response to recent evidence | Q34288307 | ||
| Tibolone for postmenopausal women: systematic review of randomized trials | Q34491645 | ||
| The effects of tibolone on mood and libido. | Q34612656 | ||
| The million women study: a critique | Q35948648 | ||
| Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group | Q36121490 | ||
| Management of menopausal symptoms in patients with breast cancer: an evidence-based approach | Q36243750 | ||
| Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users | Q36275157 | ||
| Hormone replacement therapy in women with past history of endometriosis | Q36603657 | ||
| The effects of tibolone in older postmenopausal women | Q36933363 | ||
| The use of estrogen therapy in women's sexual functioning (CME). | Q37414384 | ||
| The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study | Q39348773 | ||
| Relationship between osteoporosis and cardiovascular disease in postmenopausal women | Q40380006 | ||
| Tibolone: a compound with tissue specific inhibitory effects on sulfatase | Q40774322 | ||
| Effects of androgens on haemostasis | Q41141615 | ||
| HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped | Q42619667 | ||
| Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation | Q42686281 | ||
| Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor | Q43731056 | ||
| Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies | Q43766421 | ||
| The Million Women Study: potential biases do not allow uncritical acceptance of the data | Q43805218 | ||
| Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women | Q43813819 | ||
| Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity | Q43813839 | ||
| Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss | Q43980654 | ||
| Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators | Q43988923 | ||
| A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women | Q43992057 | ||
| Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women | Q44115504 | ||
| Effects of tibolone on plasma levels of nitric oxide in postmenopausal women | Q44127869 | ||
| Effect of tibolone treatment on intima-media thickness and the resistive indices of the carotid arteries | Q44303599 | ||
| Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women | Q44355123 | ||
| Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis | Q44478665 | ||
| Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study | Q44559210 | ||
| Estrogen plus progestin and colorectal cancer in postmenopausal women | Q44785535 | ||
| Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women | Q44809941 | ||
| Endometrial effects of tibolone. | Q44925832 | ||
| Multisystem evaluations of the long-term effects of tibolone on postmenopausal monkeys | Q45036474 | ||
| Tibolone activates nitric oxide synthesis in human endothelial cells. | Q45050647 | ||
| The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial | Q45233103 | ||
| Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction | Q46141973 | ||
| Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial | Q46148436 | ||
| The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women | Q46244173 | ||
| Hormone replacement therapy use and the risk of stroke | Q46256311 | ||
| The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. | Q46259268 | ||
| Hormone therapy and risk of myocardial infarction: a national register study | Q46338654 | ||
| Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment. Open prospective study with Doppler ultrasonography in internal carotid artery | Q46394018 | ||
| Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. | Q46394057 | ||
| Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study | Q46472616 | ||
| Effects of tibolone on selectins in postmenopausal women | Q46491055 | ||
| Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels | Q46600428 | ||
| Myocardial infarction risk and hormone replacement: differences between products | Q46615752 | ||
| Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers | Q46660405 | ||
| Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial | Q46730624 | ||
| Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women | Q46767327 | ||
| Brachial artery responses in menopausal women using tibolone | Q46836456 | ||
| Hormone replacement therapy use and variations in the risk of breast cancer | Q46849284 | ||
| Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer | Q46877675 | ||
| Does tibolone exacerbate atherosclerosis? | Q46895694 | ||
| The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study | Q46895697 | ||
| Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. | Q46905882 | ||
| Tibolone improves myocardial perfusion in postmenopausal women with ischemic heart disease: an open-label exploratory pilot study | Q46927560 | ||
| Effects of menopause and postmenopausal tibolone treatment on plasma TNFalpha, IL-4, IL-10, IL-12 cytokine pattern and some bone turnover markers | Q46964623 | ||
| Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. | Q50786172 | ||
| Changes in sex behaviour after menopause: effects of tibolone. | Q51046782 | ||
| Elevated arterial stiffness in postmenopausal women with osteoporosis. | Q51223938 | ||
| Effects of tibolone and raloxifene on health-related quality of life and sexual function. | Q51737428 | ||
| Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy. | Q51802977 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 804-814 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Gynecological Endocrinology | Q5625187 |
| P1476 | title | Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials | |
| P478 | volume | 26 |
| Q34465301 | Advances in pharmacotherapy for treating female sexual dysfunction |
| Q89993571 | Cardiovascular Risk/Benefit Profile of MHT |
| Q47556269 | Comprehensive review of cardiovascular toxicity of drugs and related agents. |
| Q33458455 | Determination of 3-α-hydroxytibolone in human plasma by LC-MS/MS: application for a pharmacokinetic study after administration of a tibolone formulation |
| Q51410425 | Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. |
| Q58796694 | Effect of tibolone on the survival of early stage cervical adenocarcinoma patients |
| Q50214759 | Effects of Human Sulfotransferase 2A1 Genetic Polymorphisms 3 on the Sulfation of Tibolone |
| Q36278198 | Effects of Tibolone on the Central Nervous System: Clinical and Experimental Approaches |
| Q51137166 | Maintaining sexuality in menopause. |
| Q48189748 | The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause. |
Search more.